2 terminated, 1 completed, 1 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Revive Therapeutics, Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder Psilocybin - Methamphetamine Use Disorder, Substance-Related Disorders | Phase 1 | Terminated | University of Wisconsin, Madison | 5 | 2023-03-03 | 2026-05-12 |
| Bucillamine in Treatment of Patients With COVID-19 Bucillamine, Placebo - Covid19 | Phase 3 | Terminated | Revive Therapeutics, Ltd. | 713 | 2020-11-27 | 2023-07-07 |
| Bucillamine Phase 2 Trial in Patients With Cystinuria Bucillamine - Cystinuria | Phase 2 | Unknown | Revive Therapeutics, Ltd. | 30 | 2017-05-01 | 2017-05-18 |
| Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout Bucillamine, Colchicine - Gout | Phase 2 | Completed | Revive Therapeutics, Ltd. | 66 | 2015-04-01 | 2016-10-05 |
COVID-19 (1) · Chemically-Induced Disorders (1) · Cystinuria (1) · Gout (1) · Substance-Related Disorders (1)
bucillamine (3) · Colchicine (1) · Psilocybin (1)
United States (4) · Puerto Rico (1)